Related references
Note: Only part of the references are listed.Bone Marrow Stromal Cells-Induced Drug Resistance in Multiple Myeloma
Roberto Ria et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Bone marrow niches in haematological malignancies
Simon Mendez-Ferrer et al.
NATURE REVIEWS CANCER (2020)
Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma
Oksana Zavidij et al.
NATURE CANCER (2020)
Multiple myeloma: Every year a new standard?
S. Vincent Rajkumar
HEMATOLOGICAL ONCOLOGY (2019)
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial
Maria-Victoria Mateos et al.
LANCET HAEMATOLOGY (2019)
The MP0250-CP201 Mirror Study: A Phase 2 Study Update of MP0250 Plus Bortezomib and Dexamethasone in Relapse/Refractory Multiple Myeloma (RRMM) Patients Previously Exposed to Proteasome Inhibitors and Immunomodulatory Drugs
Norbert Grzasko et al.
BLOOD (2019)
Daratumumab, pomalidomide and dexamethasone combination therapy in daratumumab and/or pomalidomide refractory multiple myeloma
M. Junaid Hussain et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial
Ilaria Saltarella et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Epigenetics in multiple myeloma: From mechanisms to therapy
Mohammad Alzrigat et al.
SEMINARS IN CANCER BIOLOGY (2018)
Generation of erythroid cells from polyploid giant cancer cells: re-thinking about tumor blood supply
Zhigang Yang et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2018)
Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma
Amrita Krishnan et al.
LEUKEMIA (2018)
Mesenchymal stem cells in multiple myeloma: a therapeutical tool or target?
Song Xu et al.
LEUKEMIA (2018)
The importance of antiangiogenic effect in multiple myeloma treatment
Agnieszka Barchnicka et al.
ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE (2018)
Targeting angiogenesis in multiple myeloma by the VEGF and HGF blocking DARPin® protein MP0250: a preclinical study
Luigia Rao et al.
Oncotarget (2018)
Drug resistance in multiple myeloma
Pawel Robak et al.
CANCER TREATMENT REVIEWS (2018)
Bevacizumab in advanced lung cancer: state of the art
Sandra Assoun et al.
FUTURE ONCOLOGY (2017)
Bone Niches, Hematopoietic Stem Cells, and Vessel Formation
Roberto Tamma et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Bone marrow micro-environment is a crucial player for myelomagenesis and disease progression
Patrizia Mondello et al.
ONCOTARGET (2017)
Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formation
Federica Costa et al.
ONCOTARGET (2017)
Multiple myeloma
Shaji K. Kumar et al.
NATURE REVIEWS DISEASE PRIMERS (2017)
Emerging options in multiple myeloma: targeted, immune, and epigenetic therapies
Shaji Kumar
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2017)
Diagnostic, Prognostic, and Predictive Utility of Recurrent Somatic Mutations in Myeloid Neoplasms
Umang Patel et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2017)
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma
Jonas Paludo et al.
BLOOD (2017)
A phase 2 study of panobinostat with lenalidomide and weekly dexamethasone in myeloma
Ajai Chari et al.
BLOOD ADVANCES (2017)
Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma
Torben Plesner et al.
BLOOD (2016)
Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma
Meletios A. Dimopoulos et al.
BLOOD (2016)
Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma
Inger S. Nijhof et al.
BLOOD (2016)
Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma
Rachid C. Baz et al.
BLOOD (2016)
Elotuzumab in combination with thalidomide and low-dose dexamethasone: a phase 2 single-arm safety study in patients with relapsed/refractory multiple myeloma
Maria-Victoria Mateos et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Recent advances in the development of dual VEGFR and c-Met small molecule inhibitors as anticancer drugs
Jin Zhang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2016)
Emerging antibodies for the treatment of multiple myeloma
Flora Zagouri et al.
EXPERT OPINION ON EMERGING DRUGS (2016)
Sorafenib for the treatment of multiple myeloma
Massimo Gentile et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2016)
Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial
Andrew J. Yee et al.
LANCET ONCOLOGY (2016)
Multiple Myeloma: Diagnosis and Treatment
S. Vincent Rajkumar et al.
MAYO CLINIC PROCEEDINGS (2016)
Adenosine Generated in the Bone Marrow Niche Through a CD38-Mediated Pathway Correlates With Progression of Human Myeloma
Alberto L. Horenstein et al.
MOLECULAR MEDICINE (2016)
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
P. Moreau et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Functional and Biological Role of Endothelial Precursor Cells in Tumour Progression: A New Potential Therapeutic Target in Haematological Malignancies
Antonia Reale et al.
STEM CELLS INTERNATIONAL (2016)
Escaping Antiangiogenic Therapy: Strategies Employed by Cancer Cells
Mauricio P. Pinto et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2016)
Bendamustine, lenalidomide, and dexamethasone (BRD) is highly effective with durable responses in relapsed multiple myeloma
Shaji K. Kumar et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
Thalidomide (5HPP-33) Suppresses Microtubule Dynamics and Depolymerizes the Microtubule Network by Binding at the Vinblastine Binding Site on Tubulin
Aijaz Rashid et al.
BIOCHEMISTRY (2015)
Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma
Jatin J. Shah et al.
BLOOD (2015)
The Aplidin analogs PM01215 and PM02781 inhibit angiogenesis in vitro and in vivo
Bojana Borjan et al.
BMC CANCER (2015)
Changes in circulating endothelial progenitor cells predict responses of multiple myeloma patients to treatment with bortezomib and dexamethasone
L. Wang et al.
BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH (2015)
Phase Ib/II trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed myeloma
Joseph R. Mikhael et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
Sagar Lonial et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
A. Keith Stewart et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The Analysis of the Relationship between Multiple Myeloma Cells and Their Microenvironment
Artur Jurczyszyn et al.
JOURNAL OF CANCER (2015)
Modifications of the mouse bone marrow microenvironment favor angiogenesis and correlate with disease progression from asymptomatic to symptomatic multiple myeloma
Arianna Calcinotto et al.
ONCOIMMUNOLOGY (2015)
Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma
Pieter Sonneveld et al.
BLOOD (2015)
Effectiveness of targeted therapy as monotherapy or combined therapy in patients with relapsed or refractory multiple myeloma: A systematic review and meta-analysis
Sylwia Lopuch et al.
HEMATOLOGY (2015)
Analysis of Outcomes Based on Response in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma Treated with Panobinostat or Placebo in Combination with Bortezomib and Dexamethasone in the Panorama 1 Trial: Updated Analysis Based on Prior Treatment
Jesus F. San Miguel et al.
BLOOD (2015)
Phase II study of pegylated liposomal doxorubicin, low-dose dexamethasone, and lenalidomide in patients with newly diagnosed multiple myeloma
Rachid C. Baz et al.
AMERICAN JOURNAL OF HEMATOLOGY (2014)
Role of endothelial progenitor cells in cancer progression
Michele Moschetta et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2014)
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study
Paul G. Richardson et al.
BLOOD (2014)
A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma
Paul G. Richardson et al.
BLOOD (2014)
Effects of a novel proteasome inhibitor BU-32 on multiple myeloma cells
Sudipa S. Roy et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
HIF-1α of Bone Marrow Endothelial Cells Implies Relapse and Drug Resistance in Patients with Multiple Myeloma and May Act as a Therapeutic Target
Roberto Ria et al.
CLINICAL CANCER RESEARCH (2014)
A HGF/cMET Autocrine Loop Is Operative in Multiple Myeloma Bone Marrow Endothelial Cells and May Represent a Novel Therapeutic Target
Arianna Ferrucci et al.
CLINICAL CANCER RESEARCH (2014)
Inhibition of Endothelial Slit2/Robo1 Signaling by Thalidomide Restrains Angiogenesis by Blocking the PI3K/Akt Pathway
Yinan Li et al.
DIGESTIVE DISEASES AND SCIENCES (2014)
Maintenance Therapy for Multiple Myeloma
Philip L. McCarthy et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2014)
Thalidomide-induced angiopoietin 2, Notch1 and Dll4 downregulation under hypoxic condition in tissues with gastrointestinal vascular malformation and human umbilical vein endothelial cells
Qian Feng et al.
JOURNAL OF DIGESTIVE DISEASES (2014)
Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study
Shaji K. Kumar et al.
LANCET ONCOLOGY (2014)
Bone marrow fibroblasts parallel multiple myeloma progression in patients and mice: in vitro and in vivo studies
M. A. Frassanito et al.
LEUKEMIA (2014)
Autologous Transplantation and Maintenance Therapy in Multiple Myeloma
A. Palumbo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Prognostic relevance of cancer-associated fibroblasts in human cancer
Janna Paulsson et al.
SEMINARS IN CANCER BIOLOGY (2014)
Role of tumour angiogenesis in haematological malignancies
Michael Medinger et al.
SWISS MEDICAL WEEKLY (2014)
A phase II trial of BAY 43-9006 (sorafenib) (NSC-724772) in patients with relapsing and resistant multiple myeloma: SWOG S0434
Gordan Srkalovic et al.
CANCER MEDICINE (2014)
Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib
Paul G. Richardson et al.
BLOOD (2013)
Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma
Michael Wang et al.
BLOOD (2013)
Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myelome 2009-02
Xavier Leleu et al.
BLOOD (2013)
Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study
Alessandra Larocca et al.
BLOOD (2013)
Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma
Darrell White et al.
CANCER (2013)
Phase Ib Dose-Escalation Study (PX-171-006) of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Progressive Multiple Myeloma
Ruben Niesvizky et al.
CLINICAL CANCER RESEARCH (2013)
Novel Targeting of Phospho-cMET Overcomes Drug Resistance and Induces Antitumor Activity in Multiple Myeloma
Michele Moschetta et al.
CLINICAL CANCER RESEARCH (2013)
Sorafenib in patients with refractory or recurrent multiple myeloma
Anna Yordanova et al.
HEMATOLOGICAL ONCOLOGY (2013)
Molecular classification and risk stratification of myeloma
P. Leif Bergsagel et al.
HEMATOLOGICAL ONCOLOGY (2013)
A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial
Jian Hou et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2013)
Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma
A. A. Chanan-Khan et al.
BLOOD CANCER JOURNAL (2013)
PITUITARY FOLLICULAR CELLS SECRETE A NOVEL HEPARIN-BINDING GROWTH FACTOR SPECIFIC FOR VASCULAR ENDOTHELIAL CELLS (Reprinted from BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol 161, pg 851-858, 1989)
Napoleone Ferrara et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2012)
Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study
Suzanne Lentzsch et al.
BLOOD (2012)
A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma
Andrzej J. Jakubowiak et al.
BLOOD (2012)
Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma
Michele Cavo et al.
BLOOD (2012)
Macrophages and mesenchymal stromal cells support survival and proliferation of multiple myeloma cells
Jaehyup Kim et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Multiple Myeloma Mesenchymal Stem Cells: Characterization, Origin, and Tumor-Promoting Effects
Michaela R. Reagan et al.
CLINICAL CANCER RESEARCH (2012)
Bone Marrow Microenvironment in Multiple Myeloma Progression
S. Manier et al.
JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY (2012)
Elotuzumab in Combination With Lenalidomide and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma
Sagar Lonial et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
Michel Attal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
Philip L. McCarthy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Four proteins governing overangiogenic endothelial cell phenotype in patients with multiple myeloma are plausible therapeutic targets
S. Berardi et al.
ONCOGENE (2012)
Nitric oxide rescues thalidomide mediated teratogenicity
Jamila H. Siamwala et al.
SCIENTIFIC REPORTS (2012)
Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: Results from a phase 2 trial
Shaji K. Kumar et al.
AMERICAN JOURNAL OF HEMATOLOGY (2011)
Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory multiple myeloma: a California Cancer Consortium trial
George Somlo et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Lenalidomide Restrains Motility and Overangiogenic Potential of Bone Marrow Endothelial Cells in Patients with Active Multiple Myeloma
Annunziata De Luisi et al.
CLINICAL CANCER RESEARCH (2011)
In Vitro and In Vivo Selective Antitumor Activity of a Novel Orally Bioavailable Proteasome Inhibitor MLN9708 against Multiple Myeloma Cells
Dharminder Chauhan et al.
CLINICAL CANCER RESEARCH (2011)
Apoptosis Induction by Thalidomide: Critical for Limb Teratogenicity but Therapeutic Potential in Idiopathic Pulmonary Fibrosis?
Jurgen Knobloch et al.
Current Molecular Pharmacology (2011)
VEGF/VEGFR2 interaction down-regulates matrix metalloproteinase-9 via STAT1 activation and inhibits B chronic lymphocytic leukemia cell migration
Estefania Ugarte-Berzal et al.
BLOOD (2010)
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma
Paul G. Richardson et al.
BLOOD (2010)
Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma
Guellue Goerguen et al.
BLOOD (2010)
Immunomodulatory effect of mesenchymal stem cells
C. Herrero et al.
BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH (2010)
The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II study
Stephen A. Schey et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Angiogenesis Inhibitors: Current Strategies and Future Prospects
Kristina M. Cook et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2010)
VEGFR-3 ligand-binding and kinase activity are required for lymphangiogenesis but not for angiogenesis
Luqing Zhang et al.
CELL RESEARCH (2010)
Vitamin E and rutin synergistically inhibit expression of vascular endothelial growth factor through down-regulation of binding activity of activator protein-1 in human promyelocytic leukemia (HL-60) cells
Cheng-Hung Chuang et al.
CHEMICO-BIOLOGICAL INTERACTIONS (2010)
Bortezomib and zoledronic acid on angiogenic and vasculogenic activities of bone marrow macrophages in patients with multiple myeloma
Michele Moschetta et al.
EUROPEAN JOURNAL OF CANCER (2010)
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial
S. Vincent Rajkumar et al.
LANCET ONCOLOGY (2010)
Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs
V. Ramakrishnan et al.
ONCOGENE (2010)
Identification of a Primary Target of Thalidomide Teratogenicity
Takumi Ito et al.
SCIENCE (2010)
Thalidomide-induced limb defects: resolving a 50-year-old puzzle
Neil Vargesson
BIOESSAYS (2009)
Thalidomide attenuates nitric oxide-driven angiogenesis by interacting with soluble guanylyl cyclase
Syamantak Majumder et al.
BRITISH JOURNAL OF PHARMACOLOGY (2009)
Gene Expression Profiling of Bone Marrow Endothelial Cells in Patients with Multiple Myeloma
Roberto Ria et al.
CLINICAL CANCER RESEARCH (2009)
Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma
Paul G. Richardson et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma
Martha Q. Lacy et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions
Ling Lu et al.
MICROVASCULAR RESEARCH (2009)
Lysophosphatidic acid receptor expression in chronic lymphocytic leukemia leads to cell survival mediated though vascular endothelial growth factor expression
Sekar Ashok Kumar et al.
LEUKEMIA & LYMPHOMA (2009)
Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation
Christina Therapontos et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Positive and Negative Modulation of Angiogenesis by VEGFR1 Ligands
Yihai Cao
SCIENCE SIGNALING (2009)
Endothelial differentiation of hematopoietic stem and progenitor cells from patients with multiple myeloma
Roberto Ria et al.
CLINICAL CANCER RESEARCH (2008)
Bone marrow angiogenesis and angiogenic factors in multiple myeloma treated with novel agents
M. Teresa Cibeira et al.
CYTOKINE (2008)
Mechanisms of proteasome inhibitor action and resistance in cancer
David J. McConkey et al.
DRUG RESISTANCE UPDATES (2008)
Normalization of the serum angiopoietin-1 to angiopoietin-2 ratio reflects response in refractory/resistant multiple myeloma patients treated with bortezomib
Konstantinos Anargyrou et al.
HAEMATOLOGICA (2008)
VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma
M. Pineda-Roman et al.
LEUKEMIA (2008)
Mast cells contribute to vasculogenic mimicry in multiple myeloma
Beatrice Nico et al.
STEM CELLS AND DEVELOPMENT (2008)
Vasculogenic mimicry by bone marrow macrophages in patients with multiple myeloma
C. Scavelli et al.
ONCOGENE (2008)
Zoledronic acid affects over-angiogenic phenotype of endothelial cells in patients with multiple myeloma
Claudio Scavelli et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
Meletios Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America
Donna M. Weber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial
Thierry Facon et al.
LANCET (2007)
Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma:: A report from the GIMEMA -: Italian multiple myeloma network
Antonio Palumbo et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Vascular endothelial growth factor receptor-2: Structure, function, intracellular signalling and therapeutic inhibition
Katherine Holmes et al.
CELLULAR SIGNALLING (2007)
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets
Teru Hideshima et al.
NATURE REVIEWS CANCER (2007)
Tumor cell-organ microenvironment interactions in the pathogenesis of cancer metastasis
Robert R. Langley et al.
ENDOCRINE REVIEWS (2007)
Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma
Antonio Palumbo et al.
BLOOD (2007)
The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma
William G. Kaelin
CLINICAL CANCER RESEARCH (2007)
Alternative vascularization mechanisms in cancer - Pathology and therapeutic implications
Balazs Dome et al.
AMERICAN JOURNAL OF PATHOLOGY (2007)
Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma
M. Wang et al.
HEMATOLOGY (2007)
The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma
Klaus Podar et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy
R. Baz et al.
ANNALS OF ONCOLOGY (2006)
The vascular endothelial growth factor receptor (VEGFR-1) supports growth and survival of human breast carcinoma
Yan Wu et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myelorna
Massimo Offidani et al.
BLOOD (2006)
Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications
David H. Chang et al.
BLOOD (2006)
Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myeloma
Mohamad A. Hussein et al.
MAYO CLINIC PROCEEDINGS (2006)
Targeting NF-κB in hematologic malignancies
T Braun et al.
CELL DEATH AND DIFFERENTIATION (2006)
Thalidomide attenuates nitric oxide mediated angiogenesis by blocking migration of endothelial cells
KP Tamilarasan et al.
BMC CELL BIOLOGY (2006)
Unbalanced alternative splicing and its significance in cancer
JP Venables
BIOESSAYS (2006)
Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma
A Palumbo et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2006)
Neoplastic circulating endothelial cells in multiple myeloma with 13q14 deletion
GM Rigolin et al.
BLOOD (2006)
Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled-trial
A Palumbo et al.
LANCET (2006)
Involvement of COX-2 in VEGF-induced angiogenesis via P38 and JNK pathways in vascular endothelial cells
GF Wu et al.
CARDIOVASCULAR RESEARCH (2006)
Low dose velcade, thalidomide and dexamethasone (LD-VTD): An effective regimen for relapsed and refractory multiple myeloma patients
S Ciolli et al.
LEUKEMIA & LYMPHOMA (2006)
Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells
AM Roccaro et al.
CANCER RESEARCH (2006)
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma
SV Rajkumar et al.
BLOOD (2005)
Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma
A Vacca et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Essential role for the p110δ isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia
P Sujobert et al.
BLOOD (2005)
Thalidomide-induced antiangiogenic action is mediated by ceramide through depletion of VEGF receptors, and is antagonized by sphingosine-1-phosphate
T Yabu et al.
BLOOD (2005)
Bcl-2 acts in a proangiogenic signaling pathway through nuclear factor-κB and CXC chemokines
E Karl et al.
CANCER RESEARCH (2005)
Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma
C Kyriakou et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Combined thalidomide and cyclophosphamide treatment for refractory or relapsed multiple myeloma patients: a prospective phase II study
S Hovenga et al.
ANNALS OF HEMATOLOGY (2005)
Circulating endothelial progenitor cells in multiple myeloma:: implications and significance
H Zhang et al.
BLOOD (2005)
The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications
K Podar et al.
BLOOD (2005)
Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro
K Dredge et al.
MICROVASCULAR RESEARCH (2005)
Tubulin-polymerization inhibitors derived from thalidomide
S Inatsuki et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2005)
Anti-angiogenic effect of bortezomib in patients with multiple myeloma
M Politou et al.
ACTA HAEMATOLOGICA (2005)
Therapeutic renaissance of thalidomide in the treatment of haematological malignancies
D Ribatti et al.
LEUKEMIA (2005)
Enhanced growth suppression of Philadephia leukemia cells by targeting bcr3/abI2 and VEGF through antisense strategy
XL Cong et al.
LEUKEMIA (2005)
Angiogenic switch during 5T2MM murine myeloma tumorigenesis: role of CD45 heterogeneity
K Asosingh et al.
BLOOD (2004)
The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma
R García-Sanz et al.
LEUKEMIA (2004)
Cyclooxygenase-2 induces EP1- and HER-2/Neu-dependent vascular endothelial growth factor-C up-regulation:: A novel-mechanism of lymphangiogenesis in lung adenocarcinoma
JL Su et al.
CANCER RESEARCH (2004)
Pharmacology and signaling of prostaglandin receptors: Multiple roles in inflammation and immune modulation
AN Hata et al.
PHARMACOLOGY & THERAPEUTICS (2004)
A VEGF-dependent autocrine loop mediates proliferation and capillarogenesis in bone marrow endothelial cells of patients with multiple myeloma
R Ria et al.
THROMBOSIS AND HAEMOSTASIS (2004)
Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study
K Zervas et al.
ANNALS OF ONCOLOGY (2004)
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
SM Wilhelm et al.
CANCER RESEARCH (2004)
Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma
MA Dimopoulos et al.
HEMATOLOGY JOURNAL (2004)
Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma
T Hideshima et al.
ONCOGENE (2003)
Vascular endothelial growth factor and its receptors in multiple myeloma
R Ria et al.
LEUKEMIA (2003)
Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma
MH Kropff et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
DTPACE: An effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma
CK Lee et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders
M Autiero et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2003)
The biology of VEGF and its receptors
N Ferrara et al.
NATURE MEDICINE (2003)
Peripheral blood endothelial progenitor cells are derived from monocyte/macrophages and secrete angiogenic growth factors
J Rehman et al.
CIRCULATION (2003)
Thalidomide alone or with dexamethasone for previously untreated multiple myeloma
D Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Regulation of vascular endothelial growth factor expression by insulin-like growth factor I in thyroid carcinomas
V Poulaki et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Endothelial cells in the bone marrow of patients with multiple myeloma
A Vacca et al.
BLOOD (2003)
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma
PG Richardson et al.
BLOOD (2002)
Vascular and haematopoietic stem cells:: Novel targets for anti-angiogenesis therapy?
S Rafii et al.
NATURE REVIEWS CANCER (2002)
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma
SV Rajkumar et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Misregulation of gene expression in the redox-sensitive NF-κB-dependent limb outgrowth pathway by thalidomide
JM Hansen et al.
DEVELOPMENTAL DYNAMICS (2002)
Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications
N Mitsiades et al.
BLOOD (2002)
B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules
NE Kay et al.
LEUKEMIA (2002)
Novel 4-anilinoquinazolines with C-7 basic side chains:: Design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors
LF Hennequin et al.
JOURNAL OF MEDICINAL CHEMISTRY (2002)
The role of angiogenesis in hematologic malignancies
R Stasi et al.
JOURNAL OF HEMATOTHERAPY & STEM CELL RESEARCH (2002)
5′-OH-thalidomide, a metabolite of thalidomide, inhibits angiogenesis
DK Price et al.
THERAPEUTIC DRUG MONITORING (2002)
Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration
K Podar et al.
BLOOD (2001)
Thalidomide and dexamethasone combination for refractory multiple myeloma
MA Dimopoulos et al.
ANNALS OF ONCOLOGY (2001)
Vascular endothelial growth factor and vascular adjustments to perturbations in oxygen homeostasis
Y Dor et al.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2001)
Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes
WT Bellamy et al.
BLOOD (2001)
Postnatal vasculogenesis
D Ribatti et al.
MECHANISMS OF DEVELOPMENT (2001)
Molecular aspects of multiple myeloma
NG Kastrinakis et al.
ANNALS OF ONCOLOGY (2000)
Mechanism of action in thalidomide teratogenesis
TD Stephens et al.
BIOCHEMICAL PHARMACOLOGY (2000)
Activator protein 1 (AP-1)- and nuclear factor κB (NF-κB)-dependent transcriptional events in carcinogenesis
TC Hsu et al.
FREE RADICAL BIOLOGY AND MEDICINE (2000)
Inhibition of proteasome function induces programmes cell death in proliferating endothelial cells
HCA Drexler et al.
FASEB JOURNAL (2000)
Share Paper
